Myopia

Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10

Retrieved on: 
Thursday, November 3, 2022
GLOBE, Review, Company, Presbyopia, Therapy, MAP, Myopia, NASDAQ, Mydriasis, Pharmaceutical industry

Following the release, Eyenovia management will host a conference call to review the financial and operating results.

Key Points: 
  • Following the release, Eyenovia management will host a conference call to review the financial and operating results.
  • The conference call is scheduled to begin at 4:30pm ET on Thursday, November 10, 2022.
  • A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com .
  • After the live webcast, the event will be archived on Eyenovias website for one year.

ZEISS Makes Fifth Appearance at CIIE, Placing Great Effort in Localization Strategy

Retrieved on: 
Sunday, November 6, 2022
Knowledge, Booth, Fudan University, China International Import Expo, Research, Consumer, Growth, Investment, Convention center, Eye, RMB, Multimedia, Eye and ENT Hospital of Fudan University, Institute, Industry, History, National Institute of Metrology Standardization and Industrial Quality, Suzhou Industrial Park, Health technology, CEO, View, Institute of Biophysics, Chinese Academy of Sciences, Acceleration, Myopia, Ophthalmology, ZEISS, National Exhibition and Convention Center (Shanghai), Innovation Hub, Canadian National Exhibition, Development, Solution, Telescopic sight, Renewable energy, Science, Yangtze Delta, Biophysics

During the past two years China has become the world's largest single market for ZEISS.

Key Points: 
  • During the past two years China has become the world's largest single market for ZEISS.
  • As such a localization strategy with the Chinese market at its center is imminent.
  • On November 5 ZEISS hosted a press conference of ZEISS China localization strategy at its booth in CIIE, introducing its plans in China - it will continue to increase its investments, and will thoroughly implement its localization strategy.
  • With the completion of ZEISS Guangzhou Knowledge City manufacturing base, ZEISS will possess a globally-influential industry ecosystem for healthy eyesight.

The Worldwide Age-related Macular Degeneration Industry is Expected to Reach $14.4 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 27, 2022
Pharmaceutical, Health, Optical, Association, Presbyopia, Ranibizumab, Bevacizumab, PDT, Revenue, Adoption, Industry, Astigmatism, Myopia, FDA, AMD, Lens (anatomy), Visual impairment, Macular degeneration, Severe cognitive impairment, WHO, PRK, American Association, Far-sightedness, Thr, Approximation error, Pharmaceutical industry, Cryptocurrency, LASIK, Ophthalmology

The different types of refractive errors include nearsightedness (myopia), farsightedness (hyperopia), astigmatism, and presbyopia.

Key Points: 
  • The different types of refractive errors include nearsightedness (myopia), farsightedness (hyperopia), astigmatism, and presbyopia.
  • Glasses, contact lenses, and laser eye surgery are the commonly available treatment for the correction of refractive errors.
  • Furthermore, as per the American Refractive Surgery Council, in 2017, more than 29 million LASIK procedures were performed in the US.
  • The publisher has segmented the Age-related Macular Degeneration (AMD) Market report based on product, drugs, route of administration, distribution channel, and region:
    Age-related Macular Degeneration (AMD), Product Outlook (Revenue - USD Billion, 2018 - 2030)
    Age-related Macular Degeneration (AMD), Drugs Outlook (Revenue - USD Billion, 2018 - 2030)

Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

Retrieved on: 
Thursday, October 20, 2022
U.S. Securities and Exchange Commission, Pupil, Microcline, Efficiency, Therapeutic index, New Drug Application, Myopia, NDA, NASDAQ, Patient, Lens (anatomy), MAP, Technology, Eye, Marketing, Headache, Pilocarpine, Toxicity, Incidence, Safety, Presbyopia, GLOBE, Forward-looking statement, OD, Mydriasis, FDA, COVID-19, Phenylephrine, Visual acuity, Pharmaceutical industry, Medical imaging, Risk management, Telescopic sight

VISION-2 is the fourth Phase 3 study demonstrating the utility of the companys MAP technology in improving the therapeutic index of topical ophthalmic drugs.

Key Points: 
  • VISION-2 is the fourth Phase 3 study demonstrating the utility of the companys MAP technology in improving the therapeutic index of topical ophthalmic drugs.
  • We are very pleased with these Phase 3 study results which again demonstrate the benefits of our proprietary Optejet device that underpins MicroLine as a potential on-demand treatment for presbyopia, stated Michael Rowe, Chief Executive Officer of Eyenovia.
  • We look forward to meeting with the FDA within our planned commercialization timeline in preparation for a potential new drug application (NDA) submission.
  • The VISION-2 study was a double-masked, placebo-controlled, cross-over superiority trial in which 140 subjects with presbyopia were treated.

Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia and Patients Getting Eye Exams

Retrieved on: 
Monday, October 17, 2022
U.S. Securities and Exchange Commission, Time, Refractive surgery, Therapy, Water-dropper (calligraphy), Myopia, Regulation of tobacco by the U.S. Food and Drug Administration, Society, Patient, Naitō, Eye, Technology, Food, Marketing, Severe cognitive impairment, Cataract, CEO, American Society of Cataract and Refractive Surgery, Adult, GLOBE, Presbyopia, Forward-looking statement, Mydriasis, COVID-19, Compliance, Pharmaceutical industry, Dietary supplement, Matsui

The investigational Optejet dispenser administers ophthalmic solutions horizontally using the company's proprietary Microdose Array Print (MAP) technology.

Key Points: 
  • The investigational Optejet dispenser administers ophthalmic solutions horizontally using the company's proprietary Microdose Array Print (MAP) technology.
  • The Optejet dispenser is designed to administer 1/5 the volume of solution compared to a traditional eyedropper, making doses less likely to spill or run onto the patient's face.
  • "Traditional eye drops typically overdose a patient's eye with medication and preservatives, which can lead to significant dose-related side effects," said Michael Rowe, CEO of Eyenovia.
  • It found that nearly 90% of children using the Optejet once-daily treatment successfully complied with their treatment regimen.

Ophthalmic Equipment Market by Product, End-user and Region - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 14, 2022
Hospitals, Optical, Health, Medical Devices, Adoption, Prevalence, Growth, Ophthalmology, Myopia, Perimeter, Contact lens, CAGR, Ophthalmoscopy, Lens (anatomy), Fundus photography, IOL, Slit lamp, Glasses, USD, Lists of diseases, Consumer, Hurtigruten AS, Retail, Medical device, Ultrasound, Hospital

The "Global Ophthalmic Equipment Market by Product (Spectacles, Contact Lenses, OCT Scanner, Fundus Camera, Ultrasound, Perimeter, Autorefracter, Slit Lamp, Keratometer, Tonometer, Ophthalmoscope, IOL,OVDs), End User (Consumer, Hospitals) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ophthalmic Equipment Market by Product (Spectacles, Contact Lenses, OCT Scanner, Fundus Camera, Ultrasound, Perimeter, Autorefracter, Slit Lamp, Keratometer, Tonometer, Ophthalmoscope, IOL,OVDs), End User (Consumer, Hospitals) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global ophthalmic equipment market is projected to reach USD 80.9 Billion by 2027 from USD 63.4 Billion in 2022, at a CAGR of 5.0%.
  • The vision care products segment accounted for the largest share of the ophthalmic equipment market, in 2021
    Based on products, the ophthalmic equipment market is segmented into vision care products, surgical devices, and diagnostic and monitoring devices.
  • The consumer segment hold the largest share in the ophthalmic equipment market, by end user
    Based on end users, the ophthalmic equipment market is segmented into consumers, hospitals, specialty clinics and ambulatory surgery centres, and other end users.

Professional Basketball Player Max Strus Kicks Off New Season With Upgraded Vision From Life-Changing EVO ICL Lenses

Retrieved on: 
Wednesday, October 12, 2022
Sports, Medical Supplies, Licensing (Sports), Health, Marketing, Optical, Advertising, Communications, Medical Devices, Surgery, Basketball, Quality, NASDAQ, Cornea, CEO, Myopia, Athlete, ASCRS, Refractive surgery, Intraocular lens, Iris, ICL, Cataract, Inflammation, Eye, American Society of Cataract and Refractive Surgery, Nave, Ophthalmology, Literature, FDA, Astigmatism, Glaucoma, Prevalence, Lens, Review, Society, Dioptre, Lens (anatomy), Security (finance), Multimedia, Nursing, Intention, U.S. Securities and Exchange Commission, Night vision, STAAR, Allergen, Education, Retinal implant, Partnership, Glasses, Learning, Awareness, Social media, EVO, Medical device, Telescopic sight, Health insurance, Borosilicate glass, Strus, LASIK, Life, Patient

View the full release here: https://www.businesswire.com/news/home/20221012005068/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221012005068/en/
    Max Strus, American professional basketball player, practices his on-court skills with sharper vision from EVO ICL - a new FDA-approved vision correction lens designed for the correction/reduction of myopia (nearsightedness) and astigmatism.
  • Recently, Strus had EVO lenses implanted by his doctor to upgrade his vision and break free from the hassles of eyeglasses and contact lenses.
  • Following the EVO procedure, he went from struggling with the hassles of contact lenses, both on and off the court, to having clear vision better than 20/20.
  • Starting this month, Max Strus will share his journey in national and social media campaigns which will later be expanded globally.

New TCL NXTWEAR S Glasses Unveiled on Kickstarter at Early Bird Discount

Retrieved on: 
Tuesday, October 11, 2022
PPD, TCL Technology, Sale, Computer, Electronics, Lens, Kickstarter, Atmosphere of Earth, Monsoon, General manager, Myopia, Television, Android, Microsoft Windows, Smartglasses, FHD, Research, Nose, Multimedia, Alcatel, IOS, Communication, Environment, DCI, Leisure, Nokia, TCL Electronics, View, TCL

Exclusive available on Kickstarter, the TCL NXTWEAR S campaign runs from 11th Oct to 10th Nov with a 35% Super Early Bird discount off the $449 RRP for a limited time only, giving consumers around the globe an opportunity to experience high spec, affordable smart glasses.

Key Points: 
  • Exclusive available on Kickstarter, the TCL NXTWEAR S campaign runs from 11th Oct to 10th Nov with a 35% Super Early Bird discount off the $449 RRP for a limited time only, giving consumers around the globe an opportunity to experience high spec, affordable smart glasses.
  • TCL NXTWEAR S upgrades on TCL NXTWAR Air, with a series of features that untether users from fixed screens.
  • TCL NXTWEAR S transforms mundane tasks, while enhancing leisure activities for gamers and streamers anywhere, anytime.
  • "The NXTWEAR S has received some significant upgrades and we're excited to launch on Kickstarter to offer Super Early Bird buyers a discount before it becomes widely available in December."

Global Contact Lenses Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022
Medical Supplies, Health, Medical Devices, General Health, Pharmaceutical, Optical, Biotechnology, Adoption, Color, Risk, Keratoconus, Growth, Infection, Myopia, Peripheral vision, Far-sightedness, Approximation error, Contact lens, Lens (anatomy), Cataract, Severe cognitive impairment, Inflammation, Glasses, Sport, Industry, Cornea, Incidence, Safety, Athlete, Presbyopia, COVID-19, Astigmatism, Telescopic sight, Potash

They are also launching innovative colored lenses for cosmetic purposes, which is anticipated to stimulate the growth of the market.

Key Points: 
  • They are also launching innovative colored lenses for cosmetic purposes, which is anticipated to stimulate the growth of the market.
  • Key Questions Answered in This Report:
    How has the global contact lenses market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global contact lenses market?
  • What is the structure of the global contact lenses market and who are the key players?

Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.

Retrieved on: 
Friday, September 30, 2022
Professional Football Compensation Committee, Therapy, Efficiency, COVID-19, U.S. Securities and Exchange Commission, Director, NDA, Myopia, Forward-looking statement, Presbyopia, Mydriasis, Technology, Phenylephrine, Board of directors, New Drug Application, NASDAQ, Human, Corporate governance, Board, Retirement, GLOBE, Marketing, Pharmaceutical industry

We are sorry to see Ken leave the board, but we are encouraged that he will remain available to us for advice and consultation in the future.

Key Points: 
  • We are sorry to see Ken leave the board, but we are encouraged that he will remain available to us for advice and consultation in the future.
  • We extend our gratitude and best wishes to Ken in his retirement.
  • Developed as a micro-formulation for use without anesthetic, Eyenovia believes Mydcombi will help improve the efficacy, tolerability, and efficiency of pharmacologic mydriasis.
  • Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics.